Name: GLMD Income Statement - Galmed Pharmaceuticals Revenue & EPS | Ledgeburg
Creator: Ledgeburg
License: https://creativecommons.org/licenses/by/4.0/
Keywords: Revenue, Cost of Revenue, Gross Profit, Operating Expenses, Operating Income, Net Income, EPS Basic, EPS Diluted

JavaScript is disabled. Some features may not work properly. For the best experience, please enable JavaScript in your browser.

GLMD - Galmed Pharmaceuticals Ltd.

USD | NASDAQ | Healthcare

GLMD Income Statement - Galmed Pharmaceuticals Revenue & EPS | Ledgeburg

(in millions of USD, except per-share data)	Q4 FY 25	Q3 FY 25	Q2 FY 25	Q1 FY 25	Q4 FY 24	Q3 FY 24	Q2 FY 24	Q1 FY 24	Q2 FY 23	Q1 FY 23	Q2 FY 22	Q1 FY 22	Q2 FY 21	Q1 FY 21	Q2 FY 20	Q1 FY 20	Q2 FY 19	Q1 FY 19	Q2 FY 18	Q1 FY 18	Q2 FY 17	Q2 FY 16	Q2 FY 15
Revenues
Revenues	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

(in millions of USD, except per-share data)	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012
Revenues
Revenues	-	-	-	-	-	0.0	0.0	2.0	1.1	0.5	0.0	0.0	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses
Research & Development	4.9	3.0	3.6	13.0	27.2	26.1	18.2	8.3	9.7	14.3	7.6	6.7	7.2	2.4
Operating Income
Operating Income	-	-	-	-	-	(30.2)	(22.4)	(10.7)	(12.4)	-	-	-	-	-
Non-Operating
Interest Income	-	-	-	-	-	1.2	2.0	1.0	0.2	0.4	-	-	-	-
Interest Expense
Tax & Net
Income Tax Expense	0.0	-	-	-	-	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0
Net Income From Continuing Ops
Per Share
EPS Basic	2.39	8.08	30.00	127.80	19.80	1.35	0.97	-	-	-	-	-	-	-
EPS Diluted
Supplementary Data
EBITDA	-	-	-	-	-	(30.2)	(22.3)	(10.3)	(12.1)	-	-	-	-	-
EBIT	-

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

Operating Expenses
Research & Development	-	1.1	1.1	-	-	0.7	0.5	-	0.8	-	2.6	-	7.0	-	5.0	-	3.5	-	1.9	-	2.3	3.4	1.6
Selling General & Administrative	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Selling & Marketing	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General & Administrative	-	1.0	1.1	-	-	1.3	0.7	-	1.1	-	1.2	-	1.4	-	0.8	-	1.2
Depreciation & Amortization	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of Intangibles	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Operating Expenses	-	2.1	2.1	-	-	2.0	1.2	-	1.9	-	3.7	-	8.4	-	5.8	-

Tax & Net
Income Tax Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.0	-	0.0	0.0	0.0
Net Income From Continuing Ops	12.4	(1.9)	(2.5)	(1.1)	11.8	(1.9)	(1.1)	(1.3)	(1.6)	(1.8)	(3.7)	(6.1)	(8.4)	(8.9)	(5.5)	(6.1)	(4.2)
Net Income From Discontinued Ops	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	12.4	(1.9)	(2.5)	(1.1)	11.8	(1.9)	(1.1)	(1.3)	(1.6)	(1.8)	(3.7)	(6.1)	(8.4)	(8.9)	(5.5)	(6.1)	(4.2)
Net Income Attributable To Parent	(4.8)	(1.9)	(2.5)	(1.1)	(3.2)	(1.9)	(1.1)	(1.3)	(1.6)	(1.8)	(3.7)	(6.1)	(8.4)	(8.9)	(5.5)	(6.1)
Less: Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Less: Preferred Dividends	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income To Common Shareholders	(4.8)	(1.9)	(2.5)	(1.1)	(3.2)	(1.9)	(1.1)	(1.3)	(1.6)	(1.8)	(3.7)	(6.1)	(8.4)	(8.9)	(5.5)

Per Share
EPS Basic	-	0.33	0.63	-	-	2.31	1.65	-	0.95	-	2.25	-	0.33	-	-	-	-	-	-	-	-	-	-
EPS Diluted	-	0.33	0.63	-	-	2.31	1.65	-	0.95	-	2.25	-	-	-	-	-	-	-
Shares Basic	-	5.5	3.9	-	-	0.8	0.7	-	1.7	-	1.7	-	-	-	-	-	-	-
Shares Diluted	-	5.5	3.9	-	-	0.8	0.7	-	1.7	-	1.7	-	25.1	-	-	-	-	-

Operating Income
Operating Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	(5.8)	-	(4.7)	-	-	-	-	-	-